Director/PDMR Shareholding
04/02/2022 08:08
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220204:nRSD7309Aa&default-theme=true
RNS Number : 7309A Instem plc 04 February 2022
4 February 2022
Instem plc
("Instem" or "the Company")
Exercise of Options, PDMR Dealing, Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, announces that it was notified on 2 February 2022 that
certain Directors of the Company exercised share options ("Share Options")
over, in aggregate, 100,000 ordinary shares of 10 pence each in the Company
("Ordinary Shares").
Subsequently, on 2 February 2022, certain Directors sold a portion of the
Ordinary Shares issued on the exercise of the Share Options to finance the
cost of exercise (where applicable) and associated tax liabilities.
Details of the Directors who participated in the exercise of Share Options and
subsequent sale of Ordinary Shares are as follows:
Number of: Exercise price per Ordinary Share Resultant interest in Ordinary Shares Resultant interest in Ordinary Shares (%)
Name of Director Share Options exercised Ordinary Shares sold
Phil Reason 80,000(a) 40,000 Nil 770,714 3.46%
Nigel Goldsmith 20,000(b) 12,500 176p 10,000 0.04%
(a) In relation to options granted on 22 February 2018 and exercisable on or
before 15 March 2022
(b )In relation to options granted on 7 February 2012 and exercisable on or
before 7 February 2022
Issue of Equity and Admission
Application will be made to the London Stock Exchange for the admission of the
100,000 new Ordinary Shares to trading on AIM ("New Ordinary Shares").
Admission is expected to take place at 8.00 a.m. on 9 February 2022.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the
Company's issued share capital comprises 22,289,856 Ordinary Shares. The
Company does not hold any Ordinary Shares in treasury. Therefore the total
number of voting rights in the Company is 22,289,856.
The figure of 22,289,856 may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change of their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Instem plc via Walbrook
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Rachel Hayes
Alex Bond
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study Management,
Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based
Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of
the largest 25 pharmaceutical companies, enabling clients to bring life
enhancing products to market faster. Instem's portfolio of software solutions
increases client productivity by automating study-related processes while
offering the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform during their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely associated with them
The information set out below is provided in accordance with the requirements
of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Phil Reason
2 Reason for the notification
a) Position/status Chief Executive Officer and PDMR
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Instem plc
b) LEI 213800PILYUFNNROQX68
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 10p each
Identification code GB00B3TQCK30
b) Nature of the transaction 1. Exercise of Options
2. Sale of Ordinary Shares
c) Price(s) and volume(s)
Price Volume(s)
1. Nil (exercise price) 80,000
2. 745p 40,000
d) Aggregated information n/a - the exercise of options over Ordinary Shares and the sale of Ordinary
Shares each completed as single transactions
- Aggregated volume
- Price
e) Date of the transaction 2 February 2022
f) Place of the transaction In respect of the exercise of options over Ordinary Shares: outside a trading
venue
In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market
(XLON)
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Nigel Goldsmith
2 Reason for the notification
a) Position/status Chief Financial Officer and PDMR
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Instem plc
b) LEI 213800PILYUFNNROQX68
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 10p each
Identification code GB00B3TQCK30
b) Nature of the transaction Exercise of Options
c) Price(s) and volume(s)
Price(s) Volume(s)
1. 176p (exercise price) 20,000
2. 745p 12,500
d) Aggregated information n/a - the exercise of options over Ordinary Shares and the sale of Ordinary
Shares each completed as single transactions
- Aggregated volume
- Price
e) Date of the transaction 2 February 2022
f) Place of the transaction In respect of the exercise of options over Ordinary Shares: outside a trading
venue
In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market
(XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGIGDDLGGDGDS